61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Novartis AG
Closed
105.51 -0.08
Overview
Share price change
24h
Min
104.92
Max
105.75
Income | 501M 3.2B |
|---|---|
Sales | 1.1B 13B |
P/E Sector Avg | 23.52 59.362 |
EPS | 1.57 |
Dividend yield | 3.518 |
Profit margin | 24.21 |
EBITDA | 950M 5.6B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +33.2 upside |
Dividend yield Sector Avg | 3.52% 2.35% |
|---|
Market Cap | -3.6B 214B |
|---|---|
Previous open | 105.59 |
Previous close | 105.51 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Novartis AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novartis AG Forecast
Price Target
By TipRanks
33.2% upside
12 Months Forecast
Average 140.5 USD 33.2%
High 156 USD
Low 125 USD
Based on 3 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novartis AG
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
